Ftse Mib
34.463,58
-0,40%
DAX
18.687,22
-0,21%
S&P 500
5.318,99
-0,05%
NASDAQ
16.852,39
0,12%
Bitcoin
70.163,96
0,05%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Italia BIT Sanofi (1SAN) Sanofi (1SAN) Notizie

Sanofi

1SAN
90,53
0,73 (0,81%)
Ultimo aggiornamento: 17:21:02
Dati in Delay di 15 minuti
Borsa: Italia
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
21/5/202407:30GLOBEPress Release: Sanofi, Formation Bio and OpenAI announce..
20/5/202422:54GLOBESanofi: Informations relatives au nombre de droits de vote..
20/5/202420:15GLOBECommuniqué de presse : Présentation à l’ATS et publication..
13/5/202407:00GLOBEPress Release: Sanofi adds over €1 billion for..
10/5/202408:00GLOBEPress Release: Sanofi and Novavax announce co-exclusive..
02/5/202407:00GLOBECommuniqué de presse : Des données de vie réelle concernant..
30/4/202418:00GLOBEPress Release: Annual General Meeting of April 30, 2024
25/4/202407:30GLOBECommuniqué de presse : Sanofi réitère ses objectifs..
23/4/202407:00GLOBEPress Release: Rilzabrutinib LUNA 3 phase 3 study met..
17/4/202407:00GLOBEPress Release: New 48-week frexalimab phase 2 data support..
12/4/202420:05GLOBESanofi: Informations relatives au nombre de droits de vote..
08/4/202418:00GLOBESanofi - AGM 30.04.2024 - Mise à disposition des documents..
22/3/202407:30GLOBEPress Release: Availability of the Q1 2024 Memorandum for..
15/3/202420:04GLOBESanofi: Information concerning the total number of voting..
11/3/202407:00GLOBEPress Release: New Phase 2b results for amlitelimab support..
24/2/202415:51GLOBEPress Release: Phase 2 results demonstrate rilzabrutinib..
23/2/202418:45GLOBEPress Release: Filing of the 2023 U.S. Form 20-F and French..
23/2/202407:00GLOBEPress Release: Dupixent® sBLA accepted for FDA Priority..
22/2/202419:02GLOBEPress Release: Sanofi’s Board of Directors proposes the..
20/2/202423:40GLOBESanofi: Informations relatives au nombre de droits de vote..
16/2/202407:00GLOBECommuniqué de presse : Le Japon est le premier pays dans le..
15/2/202414:00GLOBECommuniqué de presse : Des données de phase II publiées dans..
05/2/202408:00GLOBECommuniqué de presse : Entraide, conditions de travail..
01/2/202407:30GLOBEPress Release: Sanofi Delivers Solid Sales and Business EPS..
25/1/202420:30GLOBECommuniqué de presse : Dupixent® : premier et seul..
23/1/202407:30GLOBECommuniqué de presse : Sanofi va acquérir Inhibrx, Inc. et..
17/1/202422:57GLOBESanofi: Informations relatives au nombre de droits de vote..
09/1/202407:30GLOBECommuniqué de presse : Brian Foard est nommé Responsable de..
21/12/202307:30GLOBEPress Release: Sanofi announces end of program evaluating..
18/12/202321:59GLOBESanofi: Information concerning the total number of voting..
15/12/202307:30GLOBEPress Release: Availability of the Q4 2023 Memorandum for..
15/12/202307:00GLOBECommuniqué de presse : L’EMA a rendu un avis favorable pour..
11/12/202322:08GLOBEPress Release: Statement on FTC challenge to proposed..
11/12/202301:30GLOBEPress Release: Sarclisa® (isatuximab) plus KRd significantly..
07/12/202307:35GLOBECP : L’essai de phase III consacré au Sarclisa® (isatuximab)..
07/12/202303:30GLOBEPress Release: Sanofi Pipeline Transformation to Accelerate..
27/11/202307:30GLOBEPress Release: Dupixent® significantly reduced COPD..
23/11/202318:00GLOBESanofi: Information concerning the total number of voting..
27/10/202307:31GLOBECommuniqué de presse : Un troisième trimestre solide, marqué..
27/10/202307:30GLOBEPress Release: Sanofi Enters Next Chapter of Play to Win..
22/10/202321:00GLOBEPress Release: Dupixent® (dupilumab) Phase 3 Results show..
19/10/202312:00GLOBEPress Release: Sanofi delivers first medicines from Global..
18/10/202310:45GLOBECommuniqué de presse : Des données de ph III présentées au..
17/10/202320:18GLOBESanofi: Informations relatives au nombre de droits de vote..
13/10/202316:00GLOBEPress Release: Late-breaking amlitelimab Phase 2b data..
04/10/202307:00GLOBEPress Release: Sanofi and Teva announce exclusive..
03/10/202307:30GLOBECommuniqué de presse : Sanofi annonce un accord sur un..
26/9/202307:30GLOBECommuniqué de presse : La FDA accorde un examen prioritaire..
25/9/202309:00GLOBEPress Release: Once-weekly ALTUVIIIO® approved in Japan as a..
22/9/202307:30GLOBECommuniqué de presse : Mise en ligne du document « Q3 2023..
Apertura: 90,00 Min: 89,73 Max: 90,53
Chiusura: 89,80

La tua Cronologia

BIT
1SAN
Sanofi
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network